| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bbadc41aa91592752369d88100f96411 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3046
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-303 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-195 |
| filingDate |
1987-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2001-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7f3d6f844f6f06e6936d3b3f095f79c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3db3e4520da9f17e00d02e38fc5d1fa9 |
| publicationDate |
2001-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-1341281-C |
| titleOfInvention |
Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen |
| abstract |
Gastrointestinal tumors are treated by administering to a patient afflicted with a gastroin-testinal tumor, a murine monoclonal antibody which specifically binds to an epitope of 17-1A antigen, the antibody being administered parenterally in multiple doses of 100 milligrams or more per dose for a total dose of about .1 - 5 grams of antibody. The high dose murine antibody therapy is well tole-rated in patients. Further, the anti-murine anti-body response which generally develops in treated humans, surprisingly does not alter significantly the plasma half life of the murine antibody on repeat administration. Thus, high blood levels of antibody can be achieved with sequential injections of high doses to enhance transit of the antibody from intra-vascular space into the tumor bed and thus provide higher concentrations of the therapeutic antibody to the locus of action. |
| priorityDate |
1986-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |